Table 1.

Demographics and clinical characteristics of HALT-PKD Study A and B participants included in the FGF23 ancillary study according to ADPKD genotype

VariablePKD1 Truncating (n=440)PKD1 Nontruncating (n=229)PKD2 (n=132)NMD (n=63)P Value
Age, yr41±1043±1046±1044±10<0.001
Sex, n (%) male217 (49%)111 (49%)69 (52%)31 (49%)0.92
Race, n (%) white409 (93%)216 (94%)129 (98%)59 (94%)0.24
Study BP target randomization group, n (%) lowa,b98 (22%)64 (28%)(45 34%)20 (32%)0.09
Study BP medication randomization group, n (%) ACEi/ARB225 (51%)116 (49%)64 (52%)30 (52%)0.96
SBP, mm Hg128±14129±15125±14129±150.048
eGFR, ml/min per 1.73 m2c69±2772±2674±2673±240.13
BMI, kg/m227.0±5.027.9±4.627.8±5.029.3±7.00.002
Calcium, mg/dl9.4±0.59.3±0.49.4±0.49.4±0.40.41
Phosphate, mg/dl3.5±0.63.3±0.53.4±0.53.3±0.50.001
Urine albumin excretion, mg/24 h26 (16–55)21 (14–49)15 (11–32)17 (11–45)<0.001
FGF23, pg/ml55.8 (40.7–76.8)49.9 (37.7–71.0)49.0 (33.8–70.5)50.3 (39.7–67.4)0.03
1,25(OH)2D, pg/ml32.8±12.533.4±12.534.1±13.138.0±14.60.02
25(OH)D, ng/ml35.6±13.833.8±13.134.1±10.732.0±9.50.11
PTH, pg/ml45.2±25.144.0±24.140.6±23.645.7±22.70.27
htTKV, ml/mb634 (465–954)595 (440–793)470 (312–654)560 (309–836)<0.001
  • Data are mean±SD, n (%), or median (interquartile range). HALT-PKD, Halt Progression of Polycystic Kidney Disease; FGF23, fibroblast growth factor 23; ADPKD, autosomal dominant PKD; NMD, no mutation detected; ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; SBP, systolic BP; BMI, body mass index; 1,25(OH)2D, 1,25 dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; htTKV, height-adjusted total kidney volume.

  • a Randomized to a BP target of 95–110/60–75 mm Hg.

  • b These variables only apply to participants in Study A (n=458).

  • c Measured by CKD Epidemiology Collaboration equation.